Johnson & Johnson reports three‑year remission rates for TREMFYA in Crohn’s disease
Johnson & Johnson presented three‑year data from the Phase 3 GALAXI 2 and 3 studies of TREMFYA (guselkumab) in adults with moderately to severely active Crohn’s disease. At week 144, 94% of patients on the 100 mg every‑eight‑weeks regimen and 91% on the 200 mg every‑four‑weeks regimen achieved clinical remission, while 88% in each group maintained 90‑day corticosteroid‑free remission. Endoscopic remission was observed in 52% of the 100 mg cohort and 61% of the 200 mg cohort. About three‑quarters of participants stayed on therapy for the full three‑year period.
Why it matters
The high remission rates suggest strong long‑term efficacy for TREMFYA, which could support continued or expanded use in Crohn’s disease treatment. The durability of response may influence prescribing patterns and market share for Johnson & Johnson’s IBD portfolio.
Key facts
- 194% of patients receiving TREMFYA 100 mg every eight weeks achieved clinical remission at week 144. prnewswire.com
- 291% of patients receiving TREMFYA 200 mg every four weeks achieved clinical remission at week 144. prnewswire.com
- 388% of patients in both dosing groups achieved 90‑day corticosteroid‑free clinical remission. prnewswire.com
- 452% of the 100 mg cohort and 61% of the 200 mg cohort achieved endoscopic remission at week 144. prnewswire.com
- 5Approximately 74% of TREMFYA‑treated patients remained on therapy through three years. prnewswire.com
- 6Safety observations through week 144 were consistent with TREMFYA’s established safety profile. prnewswire.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.